Q-omics provides the consensus-scored SOX13 profile across patient tissues and cancer cell-line models. SOX13 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SOX13 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, SOX13 RNA expression shows 19,887 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where SOX13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX13 survival associations across molecular data types. SOX13 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX13 RNA expression–survival associations across cancer types. High SOX13 expression shows unfavorable associations in UVM, KIRP, PAAD and LUAD, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SOX13 RNA expression.
This table summarizes SOX13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX13 shows lower tumor expression in KICH, LUAD, KIRP and KIRC and higher tumor expression in LIHC and STAD. The KICH box plot shows higher SOX13 RNA expression in normal versus tumor tissue (log2 FC = −2.676, t-test p < 0.001).
This table shows molecular features associated with SOX13 in patient tissues and cancer cell lines. In patient samples, SOX13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
